Amneal Gets FDA Nod for NDA of Its Neuromuscular Disorder Treatment
Amneal Pharmaceuticals Gets FDA Approval for Pyridostigmine Bromide
Amneal Receives U.S. FDA Approval Of New Drug Application For Pyridostigmine Bromide Extended-Release Tablets
Express News | Amneal Receives U.S. FDA Approval of New Drug Application for Pyridostigmine Bromide Extended-Release Tablets
This Five-star Fund's Formula Rode Super -2-
Amneal Pharmaceuticals' (NASDAQ:AMRX) Investors Will Be Pleased With Their Stellar 193% Return Over the Last Five Years
Amneal Pharmaceuticals Inc (AMRX) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and ...
Amneal to Report Third Quarter 2024 Results on November 8, 2024
Amneal Pharmaceuticals Analyst Ratings
Truist Financial Maintains Amneal Pharmaceuticals(AMRX.US) With Buy Rating, Announces Target Price $12
Amneal Pharmaceuticals (AMRX) Gets a Buy From Truist Financial
Express News | Amneal Pharma : Truist Securities Raises Target Price to $12 From $10
Express News | Amneal Pharmaceuticals Inc - New Facilities to Cost Amneal $150 Mln-$200 Mln Over 4-5 Years
Express News | Amneal and Metsera Announce Strategic Collaboration to Develop and Supply Portfolio of Next-Generation Medicines for Obesity and Metabolic Diseases
Express News | Amneal Pharmaceuticals Inc - Eligible Patients May Qualify for $25 Copay Through Crexont Savings Program
Express News | Amneal Pharmaceuticals Inc - Crexont Now Available at U.S. Pharmacies
Amneal Launches CREXONT Extended-Release Capsules For Treatment Of Parkinson's Disease
Express News | Amneal Launches Crexont® (Carbidopa and Levodopa) Extended-Release Capsules for Treatment of Parkinson’s Disease
J.P. Morgan Maintains Amneal Pharmaceuticals(AMRX.US) With Hold Rating, Maintains Target Price $9
J.P. Morgan analyst Chris Schott maintains $Amneal Pharmaceuticals(AMRX.US)$ with a hold rating, and maintains the target price at $9.According to TipRanks data, the analyst has a success rate of 54.0
Analysts Offer Insights on Healthcare Companies: Amneal Pharmaceuticals (AMRX), Aura Biosciences Inc (AURA) and Terns Pharmaceuticals (TERN)